• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-A12B filed by PetMed Express Inc.

    12/3/24 8:39:44 AM ET
    $PETS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $PETS alert in real time by email
    8-A12B 1 pets-form8xaforrightsplan.htm 8-A12B Document

    FORM 8-A
    FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
    PURSUANT TO SECTION 12(b) OR (g) OF THE
    SECURITIES EXCHANGE ACT OF 1934

    PETMED EXPRESS, INC.
    (Exact name of registrant as specified in its charter)
    Florida65-0680967
    (State or other jurisdiction of incorporation or organization)(IRS Employer Identification No.)
    420 South Congress Avenue
    Delray Beach, Florida

    33445
    (Address of principal executive offices)(Zip Code)

         Securities to be registered pursuant to Section 12(b) of the Act:
    Title of each class
    to be registered
    Name of each exchange on which each class is to be registered
    Preferred Stock Purchase RightsNASDAQ Global Select Market
    If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box.

    If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box.

    If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.

    Securities Act registration statement or Regulation A offering statement file number to which this form relates:         N/A         (if applicable)

    Securities to be registered pursuant to Section 12(g) of the Act:
    None
    (Title of class)



    INFORMATION REQUIRED IN REGISTRATION STATEMENT
    Item 1.    Description of Registrant’s Securities To Be Registered.
    On December 2, 2024, the board of directors (the “Board”) of PetMed Express, Inc., a Florida corporation (the “Company”), adopted a rights agreement and declared a dividend of one right (a “Right”) for each outstanding share of Company common stock, par value $0.001 per share (“Common Stock”), to shareholders of record at the close of business on December 16, 2024 (the “Record Date”). The description and terms of the Rights are set forth in a rights agreement, dated as of December 3, 2024 (the “Rights Agreement”), between the Company and Continental Stock Transfer & Trust Company, a federally chartered trust company, as rights agent (and any successor rights agent, the “Rights Agent”).
    The Board adopted the Rights Plan to protect the investment of shareholders during a period in which it believes shares of the Company do not reflect the inherent value of the business or its long-term growth potential, and during which there have been recent significant accumulations of Common Stock by certain shareholders.
    The Rights Plan is intended to enable shareholders to realize the long-term value of their investment in the Company by reducing the likelihood that any entity, person, or group is able to gain a control or control-like position in the Company through open market accumulation without paying all shareholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take actions that are in the best interests of all shareholders. The rights plan does not prevent any action that the Board determines to be in the best interest of the Company and its shareholders. The Rights Plan is not intended to interfere with any sale, merger, tender, exchange offer or other business combination approved by the Board. Nor does the Rights Plan prevent the Board from considering any offer that recognizes the full value of the Company and is in the best interests of the Company and its shareholders.
    In general terms, the Rights Agreement imposes significant dilution upon any person or group (other than the Company and certain other Excluded Persons and Exempt Persons), that is or becomes the beneficial owner of 12.5% or more of the Common Stock without the prior approval of the Board following the first public announcement by the Company of the adoption of the Rights Agreement. The term “beneficial ownership” is defined in the Rights Agreement and, as more fully discussed below, includes, among other things, certain derivative arrangements. Other capitalized terms not defined herein have the meanings set forth in the Rights Agreement.
    A person or group that beneficially owns 12.5% or more of the Common Stock prior to the Company’s first public announcement of its adoption of the Rights Agreement will not trigger any dilution under the Rights Agreement so long as, subject to certain exceptions described in the Rights Agreement, it does not increase its ownership of the Common Stock at a time when it still beneficially owns 12.5% or more of the Common Stock.
    A summary of the terms of the Rights Agreement follows:
        2



    The Rights. Each Right entitles its registered holder, subject to the terms of the Rights Agreement, to purchase from the Company one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.001 per share (“Preferred Stock”), of the Company at an exercise price of $27.00 per Right, subject to adjustment (the “Purchase Price”). The Rights will attach to any shares of Common Stock that become outstanding after the Record Date and prior to the earlier of the Distribution Date (as defined below), the Redemption Date (as defined below), the Final Expiration Date (as defined below), and in certain other circumstances described in the Rights Agreement.
    Until the Distribution Date, the Rights are associated with Common Stock and evidenced by Common Stock certificates or, in the case of uncertificated shares of Common Stock, the book-entry account that evidences record ownership of such shares, which will contain a notation incorporating the Rights Agreement by reference, and the Rights are transferable with and only with the underlying shares of Common Stock. Until a Right is exercised or exchanged, the registered holder thereof, as such, will have no separate rights as a shareholder of the Company, including, without limitation, the right to vote or to receive dividends.
    Until the Distribution Date, the surrender for transfer of any shares of Common Stock will also constitute the transfer of the Rights associated with those shares. As soon as practicable after the Distribution Date, separate rights certificates will be mailed to holders of record of Common Stock as of the Distribution Date. From and after the Distribution Date, the separate rights certificates alone will represent the Rights. Except as otherwise provided in the Rights Agreement, only shares of Common Stock issued prior to the Distribution Date will be issued with Rights.
    The Rights are not exercisable prior to the Distribution Date and, thereafter, become exercisable only after such time as the Rights become no longer redeemable by the Company. Until a Right is exercised, its holder will have no separate rights as a shareholder of the Company, including the right to vote or to receive dividends. Upon the Distribution Date, any Rights held by an Acquiring Person, its Related Persons, and certain transferees thereof become null and void and may not be exercised.
    Exercisability; Separation and Distribution of Rights. Subject to certain exceptions, the Rights become exercisable and will be transferrable separately from Common Stock only upon the “Distribution Date,” which occurs upon the earlier of:
    •the close of business on the tenth (10th) Business Day after the “Shares Acquisition Date” (or such later date as may be determined by the Board prior to the Distribution Date that would otherwise have occurred); “Shares Acquisition Date” is defined as (a) the first date of public announcement that any person or group has become an “Acquiring Person,” which is defined as a person or group that, together with its Related Persons, beneficially owns 12.5% or more of the outstanding shares of Common Stock (with certain exceptions, including those described below) or (b) such other date, as determined by the Board, on which a person or group has become an Acquiring Person; or
        3



    •the close of business on the tenth (10th) business day (or such later date as may be determined by the Board prior to the Distribution Date that would otherwise have occurred) after the commencement of a tender offer or exchange offer that, if consummated, would result in a person or group becoming an Acquiring Person.
    Subject to the exceptions set forth in the Rights Agreement, an Acquiring Person does not include:
    •any Exempt Person;
    •any Existing Holder; or
    •the Company or any of its subsidiaries, any officer, director, or employee of the Company or any subsidiary of the Company in his or her capacity as such, or any employee benefit plans of the Company or any subsidiary of the Company, or any entity, trustee, or administrator holding (or acting in a fiduciary capacity in respect of) shares of capital stock of the Company for or pursuant to the terms of any such plan or for the purpose of funding any such plan or other benefits for employees of the Company or any subsidiary of the Company.
    In addition, the Rights Agreement provides that no person or group will become an Acquiring Person as a result of share purchases or issuances directly from the Company or through an underwritten offering approved by the Board. Also, a person or group will not be an Acquiring Person if the Board determines that such person or group has become an Acquiring Person inadvertently and such person or group as promptly as practicable divests a sufficient number of shares so that such person or group would no longer be an Acquiring Person.
    Certain synthetic interests in securities created by derivative positions, whether or not such interests are considered to be ownership of the underlying Common Stock or are reportable for purposes of Regulation 13D of the Securities Exchange Act of 1934, as amended, are treated as beneficial ownership of the number of shares of Common Stock equivalent to the economic exposure created by the derivative position, to the extent actual shares of Common Stock are directly or indirectly held by counterparties to the derivatives contracts. Swaps dealers unassociated with any control intent or intent to evade the purposes of the Rights Agreement are excepted from such imputed beneficial ownership.
    Final Expiration Date. The Rights will expire on the earliest to occur of (a) the close of business on December 2, 2025 (the “Final Expiration Date”), (b) the time at which the Rights are redeemed by the Company (as described below), or (c) the time at which the Rights are exchanged by the Company (as described below).
    Exempted Persons and Exempted Transactions. The Rights Agreement grants discretion to the Board to designate a person as an “Exempt Person” or to designate a transaction involving the Common Stock as an “Exempt Transaction.” Except as otherwise provided in the Rights Agreement, an “Exempt Person” cannot become an Acquiring Person under the Rights Agreement. The Board can, in its sole discretion, revoke an “Exempt Person” designation.
        4



    Flip-in Event. In the event that any person or group (other than certain exempt persons as designated by the Board) becomes an Acquiring Person (a “Flip-in Event”), each holder of a Right (other than the Acquiring Person, its Related Persons, and certain transferees thereof, whose rights automatically become null and void) will have the right to receive, upon exercise and payment of the Purchase Price, Common Stock having a value equal to two times the Purchase Price, based on the market price of our Common Stock prior to such acquisition.
    For example, at a Purchase Price of $27.00 per Right, following a Flip-in Event, each Right not owned by an Acquiring Person, its Related Persons, or certain transferees thereof would entitle its holder to purchase $54.00 worth of Common Stock for $27.00. Assuming that Common Stock had a per share value of $4.50 at that time, the holder of each valid Right would be entitled to purchase twelve (12) shares of Common Stock for $27.00.
    Flip-over Event. In the event that, after a person or group has become an Acquiring Person, any of the following occurs (each, a “Flip-over Event”):
    •the Company effects a share exchange, consolidates with, or merges with and into, any other Person;
    •any Person engages in a share exchange with or consolidates with, or merges with or into, the Company, and the Company is the continuing or surviving entity and, in connection with such share exchange, consolidation or merger, all or part of the outstanding shares of Common Stock are changed into or exchanged for stock or other securities of any other entity or cash or any other property; or
    •the Company sells or otherwise transfers, in one transaction or a series of related transactions, 50% or more of the Company’s assets, cash flow or earning power;
    each holder of a Right (except for Rights held by an Acquiring Person, its Related Persons, and certain transferees thereof, which will have been voided as described above) will have the right to acquire, upon payment of the Purchase Price, shares of the common stock of the person with whom the Company has engaged in the foregoing transaction (or its parent) a market value equal to twice the Purchase Price based on the market price of such person’s stock, prior to such merger.
    Preferred Stock Provisions. Each share of Preferred Stock, if issued: (i) will not be redeemable; (ii) will entitle the holder thereof to quarterly dividend payments $0.001 per one one-thousandth of a share or an amount equal to the dividend paid on one share of Common Stock, whichever is greater; (iii) will entitle the holder to receive $1.00 per one one-thousandth of a share or an amount equal to the payment made on one share of Common Stock, whichever is greater, (iv) will have the same voting power as one share of Common Stock; and (v) if shares of Common Stock are exchanged via merger, consolidation or a similar transaction, will entitle the holders to a payment per one one-thousandth of a share equal to the payment made on one share of Common Stock.
        5



    Anti-dilution Adjustments. Our Board may adjust the Purchase Price, the number of Preferred Shares issuable and the number of outstanding Rights to prevent dilution that may occur from a stock dividend, a stock split, a reclassification of the Preferred Shares or Common Stock, as applicable. No adjustments to the Purchase Price of less than 1% will be made.
    Redemption. At any time prior to the earlier of (i) the Distribution Date or (ii) the close of business on the Final Expiration Date, the Company may redeem all but not less than all the then outstanding Rights, at a price of $0.001 per Right (appropriately adjusted to reflect any stock split, stock dividend, reclassification, or similar transaction occurring after the date of the Rights Agreement). Immediately upon the action of the Board authorizing any redemption, the Rights will terminate and the only right of the holders of Rights will be to receive the redemption price.
    Exchange. At any time after any person or group becomes an Acquiring Person, but before an Acquiring Person, together with all Related Persons, becomes the beneficial owner of 50% or more of the outstanding shares of Common Stock, the Company may exchange the Rights (other than Rights owned by the Acquiring Person, together with all Related Persons, whose Rights will have become null and void), in whole or in part, at an exchange ratio of one share of Common Stock, or one one-thousandth of a share of Preferred Stock (or of a share of a class or series of the Company’s preferred stock having equivalent rights, preferences and privileges), per Right (subject to adjustment).
    Amendment of the Rights Agreement. The Company may from time to time, in its sole discretion, amend or supplement the Rights Agreement without the consent of the holders of the Rights for so long as the Rights are redeemable. After the Rights are no longer redeemable, the Company may not amend the Rights Agreement in a way that adversely affects holders of the Rights (other than holders of Rights that have become null and void).
    Miscellaneous. While, under presently existing U.S. federal income tax law, the distribution of the Rights should not be taxable for U.S. federal income tax purposes to shareholders or to the Company, shareholders may, depending upon the circumstances then existing, recognize taxable income in the event that the Rights become exercisable for Common Stock (or other consideration) or for common stock of the acquiring company (or its parent) or in the event of the redemption of the Rights as described above.
    The foregoing description of the Rights Agreement and the Rights does not purport to be complete and is qualified in its entirety by reference to the Rights Agreement, which is filed as Exhibit 4.1 hereto and is incorporated herein by reference.
        6



    Item 2.    Exhibits.
    Exhibit No.Description
    3.1
    Articles of Amendment to the Amended and Restated Articles of Incorporation, dated December 3, 2024.
    4.1
    Rights Agreement, dated December 3, 2024, by and between the Company and Continental Stock Transfer & Trust Company, as rights agent (which includes the Form of Rights Certificate as Exhibit B thereto).
    104Cover Page Interactive Data File (embedded within the inline XBRL document).
        7



    SIGNATURE
    Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.





    Date: December 3, 2024

    PETMED EXPRESS, INC.

    By:/s/ Sandra Campos
    Name: Sandra Campos
    Title: Chief Executive Officer and President

        

    Get the next $PETS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PETS

    DatePrice TargetRatingAnalyst
    5/25/2023$20.00Buy
    Lake Street
    1/25/2022$25.00 → $21.00Underweight
    Morgan Stanley
    1/20/2022$32.00Neutral → Buy
    Sidoti
    11/18/2021$25.00Underweight
    Morgan Stanley
    10/1/2021$28.00Hold
    Jefferies
    8/5/2021$22.00Underperform
    Credit Suisse
    More analyst ratings

    $PETS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & President Campos Sandra Yvette sold $200,090 worth of shares (60,463 units at $3.31), decreasing direct ownership by 9% to 578,524 units (SEC Form 4)

      4 - PETMED EXPRESS INC (0001040130) (Issuer)

      5/2/25 8:57:58 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Director Batushansky Peter was granted 2,527 shares (SEC Form 4)

      4 - PETMED EXPRESS INC (0001040130) (Issuer)

      4/11/25 4:17:25 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 3 filed by new insider Batushansky Peter

      3 - PETMED EXPRESS INC (0001040130) (Issuer)

      4/11/25 4:09:36 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    Financials

    Live finance-specific insights

    See more
    • PetMeds® Announces Third Quarter Fiscal 2025 Financial Results

      DELRAY BEACH, Fla., Feb. 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ:PETS) today announced its financial results for its third quarter ended December 31, 2024. Third Quarter Fiscal 2025 Financial Highlights Net sales of $53.0 million. Gross margin rate of 28.1%, an increase of 80 basis points compared to the prior year period. Adjusted EBITDA of $2.0 million compared to Adjusted EBITDA of $0.9 million in the prior year period. Continued progress on key initiatives supporting the transformation of the business. "In just nine months, we have made significant strides in our transformation journey, and I am pleased to report that

      2/10/25 4:05:00 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express, Inc. Sets Fiscal Third Quarter 2025 Earnings Call

      DELRAY BEACH, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (NASDAQ:PETS) will hold a conference call on Monday, February 10, 2025 at 4:30pm Eastern Time to discuss its financial results for the fiscal third quarter ended December 31, 2024. Financial results will be issued in a press release prior to the call. PETS management will host the conference call, followed by a question-and-answer period. Please call the conference telephone number 5-10 minutes prior to the start time. Date: Monday, February 10, 2025Time: 4:30pm Eastern Time (1:30pm Pacific Time)U.S. dial-in number: 877-407-0789International number: 201-689-8562Webcast

      1/30/25 4:05:00 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMeds® Adopts Limited Duration Shareholder Rights Plan

      DELRAY BEACH, Fla., Dec. 03, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ:PETS) ("PetMeds" or the "Company"), today announced that its Board of Directors (the "Board") has adopted a limited duration shareholder rights plan to protect the best interests of all PetMeds shareholders (the "Rights Plan"). The Board adopted the Rights Plan to protect the investment of shareholders during a period in which it believes shares of the Company do not reflect the inherent value of the business or its long-term growth potential, and during which there have been recent significant accumulations of Company common stock by certain shareholders.

      12/3/24 8:30:00 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    Leadership Updates

    Live Leadership Updates

    See more
    • PetMeds® to Ring Nasdaq Opening Bell in Celebration of National Pet Day on April 11th

      DELRAY BEACH, Fla., April 11, 2025 (GLOBE NEWSWIRE) -- In celebration of National Pet Day, PetMed Express, Inc. (NASDAQ:PETS)—the original consumer pet healthcare company serving dogs, cats, and horses for nearly 30 years—will ring the Nasdaq Opening Bell this Friday, April 11, 2025. This momentous occasion honors the powerful bond between people and their pets and will feature adoptable rescue dogs from Bidawee, one of the nation's oldest no-kill animal welfare organizations. It's a tribute to the joy and unconditional love pets bring into our lives–and a reminder of how many still await families of their own. "Our pets are more than just animals; they are family," said Sandra Campo

      4/11/25 9:00:00 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express, Inc. Announces Appointment of Peter Batushansky to Board of Directors

      Former pet industry executive with more than 20 years of experience across retail, pet, healthcare, and private equity Third independent director to join the Board since 2024 Longtime board member and former Chairman Dr. Gian Fulgoni will retire DELRAY BEACH, Fla., April 09, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., parent company of PetMeds and PetCareRx, (NASDAQ:PETS) (the "Company") today announced the appointment of Peter Batushansky to the Company's Board of Directors ("the Board"), effective April 09, 2025. Mr. Batushansky is currently a Partner at L2 Capital Partners and brings to the Board more than 20 years of experience across retail, pet, healthcare and private equity, i

      4/9/25 8:00:00 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express, Inc. Announces Appointment of Robyn D'Elia as Chief Financial Officer

      DELRAY BEACH, Fla., Sept. 12, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (NASDAQ:PETS) (the "Company") today announced the appointment of retail and ecommerce veteran Robyn D'Elia as Chief Financial Officer ("CFO") effective September 16, 2024. D'Elia brings over 25 years of experience in financial leadership and strategic planning across multiple industries, including 24 years at Bed Bath & Beyond where she served in senior leadership roles across finance for two decades, and served as CFO from 2018 to 2020. Most recently D'Elia served as CFO at Odeko, a privately held all-in-one operations partner for independent coffee shops, cafes and ot

      9/12/24 8:00:00 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PetMed Express Inc.

      SC 13G - PETMED EXPRESS INC (0001040130) (Subject)

      11/14/24 4:02:14 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G filed by PetMed Express Inc.

      SC 13G - PETMED EXPRESS INC (0001040130) (Subject)

      10/10/24 6:26:43 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by PetMed Express Inc. (Amendment)

      SC 13G/A - PETMED EXPRESS INC (0001040130) (Subject)

      2/13/24 5:12:03 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Nina Capital Holdings Inc. bought $408,500 worth of shares (100,000 units at $4.08), increasing direct ownership by 4% to 2,500,000 units (SEC Form 4)

      4 - PETMED EXPRESS INC (0001040130) (Issuer)

      3/19/25 4:19:50 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Large owner Nina Capital Holdings Inc. bought $411,000 worth of shares (100,000 units at $4.11), increasing direct ownership by 4% to 2,400,000 units (SEC Form 4)

      4 - PETMED EXPRESS INC (0001040130) (Issuer)

      3/11/25 4:15:04 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Large owner Nina Capital Holdings Inc. bought $216,250 worth of shares (50,000 units at $4.33), increasing direct ownership by 2% to 2,300,000 units (SEC Form 4)

      4 - PETMED EXPRESS INC (0001040130) (Issuer)

      3/4/25 4:16:01 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PetMed Express, Inc. and Dutch Announce Partnership to Provide Accessible Telehealth Services for Pets

      DELRAY BEACH, Fla. and OAKLAND, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., parent company of PetMeds and PetCareRx (NASDAQ:PETS), today announced a new strategic partnership with virtual veterinary care provider Dutch. The collaboration marks PetMeds' latest move to expand its provider ecosystem with affordable, accessible pet healthcare options. The new partnership will enable pet parents to leverage Dutch's convenient technology and veterinary team to secure prescriptions for PetMeds' broad selection of medications in a timely manner. "This partnership expands the accessibility of pet telemedicine, which can help fill gaps in care, as the nationwide vet shortage has

      5/7/25 9:08:06 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMeds® to Ring Nasdaq Opening Bell in Celebration of National Pet Day on April 11th

      DELRAY BEACH, Fla., April 11, 2025 (GLOBE NEWSWIRE) -- In celebration of National Pet Day, PetMed Express, Inc. (NASDAQ:PETS)—the original consumer pet healthcare company serving dogs, cats, and horses for nearly 30 years—will ring the Nasdaq Opening Bell this Friday, April 11, 2025. This momentous occasion honors the powerful bond between people and their pets and will feature adoptable rescue dogs from Bidawee, one of the nation's oldest no-kill animal welfare organizations. It's a tribute to the joy and unconditional love pets bring into our lives–and a reminder of how many still await families of their own. "Our pets are more than just animals; they are family," said Sandra Campo

      4/11/25 9:00:00 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express, Inc. Announces Appointment of Peter Batushansky to Board of Directors

      Former pet industry executive with more than 20 years of experience across retail, pet, healthcare, and private equity Third independent director to join the Board since 2024 Longtime board member and former Chairman Dr. Gian Fulgoni will retire DELRAY BEACH, Fla., April 09, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., parent company of PetMeds and PetCareRx, (NASDAQ:PETS) (the "Company") today announced the appointment of Peter Batushansky to the Company's Board of Directors ("the Board"), effective April 09, 2025. Mr. Batushansky is currently a Partner at L2 Capital Partners and brings to the Board more than 20 years of experience across retail, pet, healthcare and private equity, i

      4/9/25 8:00:00 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    SEC Filings

    See more
    • PetMed Express Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PETMED EXPRESS INC (0001040130) (Filer)

      4/9/25 9:24:45 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 10-Q filed by PetMed Express Inc.

      10-Q - PETMED EXPRESS INC (0001040130) (Filer)

      2/10/25 5:14:56 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PETMED EXPRESS INC (0001040130) (Filer)

      2/10/25 5:12:32 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on PetMed Express with a new price target

      Lake Street initiated coverage of PetMed Express with a rating of Buy and set a new price target of $20.00

      5/25/23 9:17:49 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Morgan Stanley reiterated coverage on PetMed Express with a new price target

      Morgan Stanley reiterated coverage of PetMed Express with a rating of Underweight and set a new price target of $21.00 from $25.00 previously

      1/25/22 10:17:17 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express upgraded by Sidoti with a new price target

      Sidoti upgraded PetMed Express from Neutral to Buy and set a new price target of $32.00

      1/20/22 9:13:56 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples